Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 3/2014

01-06-2014 | Original Investigation

Distinctive cytokine, chemokine, and antibody responses in Echinococcus multilocularis-infected patients with cured, stable, or progressive disease

Authors: Xiangsheng Huang, Beate Grüner, Christian J. Lechner, Peter Kern, Peter T. Soboslay

Published in: Medical Microbiology and Immunology | Issue 3/2014

Login to get access

Abstract

Metacestode larvae of the tapeworm Echinococcus multilocularis can cause alveolar echinococcosis (AE), a severe parasitic disease in man, which, if it remains untreated, may cause organ failure and death. Spontaneous and parasite antigen-induced cellular responses were studied in patients with cured, stable, and progressive AE to differentiate the response profiles between the distinct states of infection. Antibody reactivity was evaluated in AE patients with cured, stable, and progressive disease. The spontaneous cellular release of pro-inflammatory IL-31 and IL-33 was clearly depressed in all AE patients, while regulatory IL-27, anti-inflammatory SDF-1/CXCL12, and eosinophil granulocyte attracting Eotaxin-1, Eotaxin-2, and Eotaxin-3 (CCL11, CCL24, CCL26) were enhanced with disease progression. Such distinctive response profiles could be applied for monitoring of AE disease progression or regression. E. multilocularis metacestode (Em) antigens (entire metacestode EmAg as well as EmVesicles) stimulated in vitro IL-31, IL-33, Eotaxin-1, Eotaxin-3, and CXCL12 cytokine and chemokine responses, which were similarly present in all AE patient groups, while regulatory IL-27 was suppressed and pro-inflammatory Eotaxin-2 was enhanced. E. multilocularis metacestode-specific IgG1, IgG3, and IgE responses progressively diminished with regression from active to stable and cured AE. IgG2 and IgG4 reactivity remained similarly high in stable and progressive cases, and lessened only with cured AE. Antibody reactivity against E. multilocularis vesicle antigen distinctively separated between cured, stable, or progressive AE, with the exception of IgG4. In sum, the combined and longitudinal study of several cytokines and chemokines, together with the evaluation of E. multilocularis vesicle-specific antibody responses, should provide a better understanding of the immune response during progression and regression of AE, and may help to improve the staging of AE patients.
Literature
1.
Gottstein B, Saucy F, Deplazes P, Reichen J, Demierre G, Busato A, Zuercher C, Pugin P (2001) Is high prevalence of Echinococcus multilocularis in wild and domestic animals associated with disease incidence in humans? Emerg Infect Dis 7(3):408–412PubMedCentralPubMedCrossRef
2.
Bresson-Hadni S, Laplante JJ, Lenys D, Rohmer P, Gottstein B, Jacquier P, Mercet P, Meyer JP, Miguet JP, Vuitton DA (1994) Seroepidemiologic screening of Echinococcus multilocularis infection in a European area endemic for alveolar echinococcosis. Am J Trop Med Hyg 51(6):837–846PubMed
3.
Rausch RL, Wilson JF, Schantz PM, McMahon BJ (1987) Spontaneous death of Echinococcus multilocularis: cases diagnosed serologically (by Em2 ELISA) and clinical significance. Am J Trop Med Hyg 36(3):576–585PubMed
4.
5.
Maizels RM, Sartono E, Kurniawan A, Partono F, Selkirk ME, Yazdanbakhsh M (1995) T-cell activation and the balance of antibody isotypes in human lymphatic filariasis. Parasitol Today 11(2):50–56PubMedCrossRef
6.
Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA (1991) Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 349(6306):243–245PubMedCrossRef
7.
Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17(3):138–146PubMedCrossRef
8.
Dreweck CM, Luder CG, Soboslay PT, Kern P (1997) Subclass-specific serological reactivity and IgG4-specific antigen recognition in human echinococcosis. Trop Med Int Health 2(8):779–787PubMedCrossRef
9.
Wen H, Craig PS, Ito A, Vuitton DA, Bresson-Hadni S, Allan JC, Rogan MT, Paollilo E, Shambesh M (1995) Immunoblot evaluation of IgG and IgG-subclass antibody responses for immunodiagnosis of human alveolar echinococcosis. Ann Trop Med Parasitol 89(5):485–495PubMed
10.
Tappe D, Gruner B, Kern P, Frosch M (2008) Evaluation of a commercial Echinococcus Western Blot assay for serological follow-up of patients with alveolar echinococcosis. Clin Vaccine Immunol 15(11):1633–1637PubMedCentralPubMedCrossRef
11.
Vuitton DA (2003) The ambiguous role of immunity in echinococcosis: protection of the host or of the parasite? Acta Trop 85(2):119–132PubMedCrossRef
12.
Sturm D, Menzel J, Gottstein B, Kern P (1995) Interleukin-5 is the predominant cytokine produced by peripheral blood mononuclear cells in alveolar echinococcosis. Infect Immun 63(5):1688–1697PubMedCentralPubMed
13.
Godot V, Harraga S, Beurton I, Deschaseaux M, Sarciron E, Gottstein B, Vuitton DA (2000) Resistance/susceptibility to Echinococcus multilocularis infection and cytokine profile in humans. I. Comparison of patients with progressive and abortive lesions. Clin Exp Immunol 121(3):484–490PubMedCentralPubMedCrossRef
14.
Hubner MP, Manfras BJ, Margos MC, Eiffler D, Hoffmann WH, Schulz-Key H, Kern P, Soboslay PT (2006) Echinococcus multilocularis metacestodes modulate cellular cytokine and chemokine release by peripheral blood mononuclear cells in alveolar echinococcosis patients. Clin Exp Immunol 145(2):243–251PubMedCentralPubMedCrossRef
15.
Lechner CJ, Gruner B, Huang X, Hoffmann WH, Kern P, Soboslay PT (2012) Parasite-specific IL-17-type cytokine responses and soluble IL-17 receptor levels in alveolar echinococcosis patients. Clin Dev Immunol 2012:735342PubMedCentralPubMedCrossRef
16.
Shin HD, Kim LH, Park BL, Jung JH, Kim JY, Chung IY, Kim JS, Lee JH, Chung SH, Kim YH, Park HS, Choi JH, Lee YM, Park SW, Choi BW, Hong SJ, Park CS (2003) Association of Eotaxin gene family with asthma and serum total IgE. Hum Mol Genet 12(11):1279–1285PubMedCrossRef
17.
Sousa-Pereira SR, Teixeira AL, Silva LC, Souza AL, Antunes CM, Teixeira MM, Lambertucci JR (2006) Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in Schistosoma mansoni myeloradiculopathy. Parasite Immunol 28(9):473–478PubMedCrossRef
18.
Charlot-Rabiega P, Bardel E, Dietrich C, Kastelein R, Devergne O (2011) Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells. J Biol Chem 286(31):27350–27362PubMedCentralPubMedCrossRef
19.
Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N (2011) IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol 41(1):47–59PubMedCrossRef
20.
Guzzo C, Che Mat NF, Gee K (2010) Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J Biol Chem 285(32):24404–24411PubMedCentralPubMedCrossRef
21.
Ezzat MH, Hasan ZE, Shaheen KY (2011) Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 25(3):334–339PubMedCrossRef
22.
Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5(7):752–760PubMedCrossRef
23.
Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, Saito H, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M (2008) Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 88(11):1245–1253PubMedCrossRef
24.
Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, Sonobe Y, Takeuchi H, Mizuno T, Suzumura A (2011) Production and functions of IL-33 in the central nervous system. Brain Res 1385:8–17PubMedCrossRef
25.
26.
Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, Delabrousse E, Kratzer W, Bresson-Hadni S (2006) WHO classification of alveolar echinococcosis: principles and application. Parasitol Int 55(Suppl):S283–S287PubMedCrossRef
27.
Dreweck CM, Soboslay PT, Schulz-Key H, Gottstein B, Kern P (1999) Cytokine and chemokine secretion by human peripheral blood cells in response to viable Echinococcus multilocularis metacestode vesicles. Parasite Immunol 21(8):433–438PubMedCrossRef
28.
Hemphill A, Stettler M, Walker M, Siles-Lucas M, Fink R, Gottstein B (2003) In vitro culture of Echinococcus multilocularis and Echinococcus vogeli metacestodes: studies on the host–parasite interface. Acta Trop 85(2):145–155PubMedCrossRef
29.
Soboslay PT, Luder CG, Hoffmann WH, Michaelis I, Helling G, Heuschkel C, Dreweck CM, Blanke CH, Pritze S, Banla M et al (1994) Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection. Clin Exp Immunol 96(2):238–244PubMedCentralPubMedCrossRef
30.
Kocherscheidt L, Flakowski AK, Gruner B, Hamm DM, Dietz K, Kern P, Soboslay PT (2008) Echinococcus multilocularis: inflammatory and regulatory chemokine responses in patients with progressive, stable and cured alveolar echinococcosis. Exp Parasitol 119(4):467–474PubMedCrossRef
31.
Eger A, Kirch A, Manfras B, Kern P, Schulz-Key H, Soboslay PT (2003) Pro-inflammatory (IL-1beta, IL-18) cytokines and IL-8 chemokine release by PBMC in response to Echinococcus multilocularis metacestode vesicles. Parasite Immunol 25(2):103–105PubMedCrossRef
32.
Luster AD (2002) The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 14(1):129–135PubMedCrossRef
33.
Anderson CF, Stumhofer JS, Hunter CA, Sacks D (2009) IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol 183(7):4619–4627PubMedCentralPubMedCrossRef
34.
Cornelissen C, Luscher-Firzlaff J, Baron JM, Luscher B (2012) Signaling by IL-31 and functional consequences. Eur J Cell Biol 91(6–7):552–566PubMedCrossRef
35.
Kasraie S, Niebuhr M, Werfel T (2010) Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 65(6):712–721PubMedCrossRef
36.
Nile CJ, Barksby E, Jitprasertwong P, Preshaw PM, Taylor JJ (2010) Expression and regulation of interleukin-33 in human monocytes. Immunology 130(2):172–180PubMedCentralPubMedCrossRef
37.
Rostan O, Gangneux JP, Piquet-Pellorce C, Manuel C, McKenzie AN, Guiguen C, Samson M, Robert-Gangneux F (2013) The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani. MBio 4(5):e00383–e00413PubMedCentralPubMedCrossRef
38.
Jones LA, Roberts F, Nickdel MB, Brombacher F, McKenzie AN, Henriquez FL, Alexander J, Roberts CW (2010) IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol 40(2):426–436PubMedCrossRef
39.
Ayimba E, Hegewald J, Segbena AY, Gantin RG, Lechner CJ, Agosssou A, Banla M, Soboslay PT (2011) Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria. Clin Exp Immunol 166(2):218–226PubMedCentralPubMedCrossRef
40.
Rakha NK, Dixon JB, Carter SD, Craig PS, Jenkins P, Folkard S (1991) Echinococcus multilocularis antigens modify accessory cell function of macrophages. Immunology 74(4):652–656PubMedCentralPubMed
41.
Kizaki T, Ishige M, Bingyan W, Kumagai M, Day NK, Good RA, Onoe K (1993) Interleukin-1-dependent mitogenic responses induced by protoscoleces of Echinococcus multilocularis in murine lymphocytes. J Leukoc Biol 53(3):233–239PubMed
42.
Kizaki T, Kobayashi S, Ogasawara K, Day NK, Good RA, Onoe K (1991) Immune suppression induced by protoscoleces of Echinococcus multilocularis in mice. Evidence for the presence of CD8dull suppressor cells in spleens of mice intraperitoneally infected with E. multilocularis. J Immunol 147(5):1659–1666PubMed
43.
Gottstein B, Haag K, Walker M, Matsumoto J, Mejri N, Hemphill A (2006) Molecular survival strategies of Echinococcus multilocularis in the murine host. Parasitol Int 55(Suppl):S45–S49PubMedCrossRef
44.
Emery I, Liance M, Leclerc C (1997) Secondary Echinococcus multilocularis infection in A/J mice: delayed metacestode development is associated with Th1 cytokine production. Parasite Immunol 19(11):493–503PubMedCrossRef
45.
Zhang W, You H, Li J, Zhang Z, Turson G, Aili H, Wang J, McManus DP (2003) Immunoglobulin profiles in a murine intermediate host model of resistance for Echinococcus granulosus infection. Parasite Immunol 25(3):161–168PubMedCrossRef
46.
Al-Qaoud KM, Abdel-Hafez SK (2005) Humoral and cytokine response during protection of mice against secondary hydatidosis caused by Echinococcus granulosus. Parasitol Res 98(1):54–60PubMedCrossRef
47.
Jenne L, Kilwinski J, Scheffold W, Kern P (1997) IL-5 expressed by CD4+ lymphocytes from Echinococcus multilocularis-infected patients. Clin Exp Immunol 109(1):90–97PubMedCentralPubMedCrossRef
48.
Evans CA, Garcia HH, Hartnell A, Gilman RH, Jose PJ, Martinez M, Remick DG, Williams TJ, Friedland JS (1998) Elevated concentrations of eotaxin and interleukin-5 in human neurocysticercosis. Infect Immun 66(9):4522–4525PubMedCentralPubMed
49.
Intapan PM, Niwattayakul K, Sawanyawisuth K, Chotmongkol V, Maleewong W (2007) Cerebrospinal fluid eotaxin and eotaxin-2 levels in human eosinophilic meningitis associated with angiostrongyliasis. Cytokine 39(2):138–141PubMedCrossRef
50.
del Pozo V, Arrieta I, Tunon T, Cortegano I, Gomez B, Cardaba B, Gallardo S, Rojo M, Renedo G, Palomino P, Tabar AI, Lahoz C (1999) Immunopathogenesis of human gastrointestinal infection by Anisakis simplex. J Allergy Clin Immunol 104(3 Pt 1):637–643PubMedCrossRef
51.
Petering H, Kluthe C, Dulkys Y, Kiehl P, Ponath PD, Kapp A, Elsner J (2001) Characterization of the CC chemokine receptor 3 on human keratinocytes. J Invest Dermatol 116(4):549–555PubMedCrossRef
52.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56PubMedCrossRef
53.
Berahovich RD, Zabel BA, Lewen S, Walters MJ, Ebsworth K, Wang Y, Jaen JC, Schall TJ (2014) Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Immunology 141(1):111–122PubMedCrossRef
54.
Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, Baleux F, Portier A, Durand-Gasselin I, Coffman RL, Galanaud P, Peuchmaur M, Emilie D (2003) Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 170(6):3392–3400PubMedCrossRef
55.
Karin N (2010) The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J Leukoc Biol 88(3):463–473PubMedCrossRef
56.
Negrete-Garcia MC, Velazquez JR, Popoca-Coyotl A, Montes-Vizuet AR, Juarez-Carvajal E, Teran LM (2010) Chemokine (C-X-C motif) ligand 12/stromal cell-derived factor-1 is associated with leukocyte recruitment in asthma. Chest 138(1):100–106PubMed
57.
Hussain R, Grogl M, Ottesen EA (1987) IgG antibody subclasses in human filariasis. Differential subclass recognition of parasite antigens correlates with different clinical manifestations of infection. J Immunol 139(8):2794–2798PubMed
58.
Daeki AO, Craig PS, Shambesh MK (2000) IgG-subclass antibody responses and the natural history of hepatic cystic echinococcosis in asymptomatic patients. Ann Trop Med Parasitol 94(4):319–328PubMed
59.
Wen H, Craig PS (1994) Immunoglobulin G subclass responses in human cystic and alveolar echinococcosis. Am J Trop Med Hyg 51(6):741–748PubMed
60.
Rigano R, Profumo E, Ioppolo S, Notargiacomo S, Ortona E, Teggi A, Siracusano A (1995) Immunological markers indicating the effectiveness of pharmacological treatment in human hydatid disease. Clin Exp Immunol 102(2):281–285PubMedCentralPubMedCrossRef
61.
Gottstein B, Eckert J, Woodtli W (1984) Determination of parasite-specific immunoglobulins using the ELISA in patients with echinococcosis treated with mebendazole. Z Parasitenkd 70(3):385–389PubMedCrossRef
62.
Wellinghausen N, Jochle W, Reuter S, Flegel WA, Grunert A, Kern P (1999) Zinc status in patients with alveolar echinococcosis is related to disease progression. Parasite Immunol 21(5):237–241PubMedCrossRef
63.
Metadata
Title
Distinctive cytokine, chemokine, and antibody responses in Echinococcus multilocularis-infected patients with cured, stable, or progressive disease
Authors
Xiangsheng Huang
Beate Grüner
Christian J. Lechner
Peter Kern
Peter T. Soboslay
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 3/2014
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-014-0331-8

Other articles of this Issue 3/2014

Medical Microbiology and Immunology 3/2014 Go to the issue

Original Investigation

Detection of Mycobacterium avium subspecies paratuberculosis in patients with Crohn’s disease is unrelated to the presence of single nucleotide polymorphisms rs2241880 (ATG16L1) and rs10045431 (IL12B)

Original Investigation

Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients

Original Investigation

Cholecystokinin protects rats against sepsis induced by Staphylococcus aureus

Original Investigation

Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination

Original Investigation

Oral administration of Shiga toxin-producing Escherichia coli induces intestinal and systemic specific immune response in mice

Original Investigation

Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits